Latest Articles
Sarina Yang
·
18 hours ago
NeuShen Therapeutics announced the closure of a $20 million Series pre-A financing round led by LAPAM capital. More news from MabPlex.
News
PharmaDJ
·
Yesterday
PharmaDJ will take a brief publishing break from October 1 to 9 in observance of China’s National Day holiday.
News
Sarina Yang
·
Yesterday
Almirall will be granted exclusive rights to develop and commercialize SIM0278 for all indications outside of the Greater China region. Simcere will receive a $15 million upfront payment and up to $492 million in milestone payments. More news from JHM Biopharma, Lepu Biopharma, MSD, Sinopharm, Henlius Biotech.
News
Shi Yingzi
·
2 days ago
August saw eight drug licensing deals, including five in-licensing agreements, an out-licensing deal and two partnerships between domestic companies.
China Deals Tracker
Sarina Yang
·
2 days ago
Zai Lab announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in Greater China. More news from Jiuzhou Pharma, Joincare Pharmaceutical.
News
Sarina Yang
·
3 days ago
Xuanzhu Biopharmaceutical, Sihuan Pharm’s holding company, has filed for an IPO with the STAR Market to raise RMB 2.47 billion ($345.22 million). More news from SingMed, MSD, Gluetacs Therapeutics, LongBio Pharma, Hansoh Pharma, BIOHENG, Brii Biosciences.
News
Danni Yin
·
4 days ago
Huisheng Biopharmaceutical, a non-wholly owned subsidiary of Sihuan Pharmaceutical, announced that it completed Series A financing worth RMB 500 million RMB ($70 million). The round was led by China Life Private Equity Investment, Grand Flight Investment, Yuanyi Jimao Equity Investment and Ginko Capital.
News
Danni Yin
·
5 days ago
Since 2021, Induced multifunctional stem cells (iPSC) have triggered a funding boom and several Chinese companies rushing into the iPSC space.
Feature
Sarina Yang
·
8 days ago
YouJia Bio announced the completion of a Series A+ round of financing worth tens of millions of RMB. It was led exclusively by the ChengZhang Group. More news from AstraZeneca, MSD, Hepa Thera Bio, Fosun Pharma.
News
Sarina Yang
·
8 days ago
Chimigen Bio has closed an initial funding round worth over 100 million RMB ($14.11 million) led by Lapam Capital and followed by Puhua Capital and Kingfriend Pharma. More news from CTTQ Pharma, Inventiva Pharma, Merck.
News